
CStone Pharmaceuticals
HKEX:2616

Net Margin
CStone Pharmaceuticals
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CN |
![]() |
CStone Pharmaceuticals
HKEX:2616
|
10.1B HKD |
-22%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
333B USD |
7%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
162B USD |
17%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
140.7B USD |
21%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD |
-9%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
130.8B AUD |
18%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.4B USD |
32%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
CStone Pharmaceuticals
Glance View
Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CStone Pharmaceuticals's most recent financial statements, the company has Net Margin of -22.4%.